Astrocytoma
|
0.200 |
Biomarker
|
disease |
HPO |
|
|
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Astrocytomas WHO grade II exhibited IDH1 mutations in 38 cases (76%) but neither IDH2 mutations nor BRAF fusions.
|
19543740 |
2009 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We found 165 IDH1 (72.7%) and 2 IDH2 mutations (0.9%) in 227 diffuse astrocytomas WHO grade II, 146 IDH1 (64.0%) and 2 IDH2 mutations (0.9%) in 228 anaplastic astrocytomas WHO grade III, 105 IDH1 (82.0%) and 6 IDH2 mutations (4.7%) in 128 oligodendrogliomas WHO grade II, 121 IDH1 (69.5%) and 9 IDH2 mutations (5.2%) in 174 anaplastic oligodendrogliomas WHO grade III, 62 IDH1 (81.6%) and 1 IDH2 mutations (1.3%) in 76 oligoastrocytomas WHO grade II and 117 IDH1 (66.1%) and 11 IDH2 mutations (6.2%) in 177 anaplastic oligoastrocytomas WHO grade III.
|
19554337 |
2009 |
Astrocytoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Mutations in isocitrate dehydrogenase enzyme isoforms 1 (IDH1) and 2 (IDH2) have been identified in many adult astrocytomas and oligodendrogliomas.
|
19915484 |
2009 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations were present in 86% of the 49 progressive astrocytomas.No mutations in IDH2 were found.
|
19933982 |
2009 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the isocitrate dehydrogenase (IDH) metabolic enzymes IDH1 and IDH2 have been found to be frequent and early genetic alterations in astrocytomas and oligodendrogliomas.
|
19996293 |
2009 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The association between TP53 and IDH mutation was significant in diffuse astrocytomas (P = 0.0018).
|
22136423 |
2012 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2) genes are mutated in 50-80% of astrocytomas, oligodendrogliomas or oligoastrocytomas of grades II and III, and secondary glioblastomas; they are, however, seldom mutated in primary glioblastomas and never in other types of glioma.
|
22399191 |
2012 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The presence of IDH mutations fails to demonstrate a significant influence on survival in the multivariate analysis of LGA patients.
|
22410704 |
2012 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We have elucidated molecularly distinct subclasses of lower grade diffuse astrocytic glioma that dictate clinical behavior and show fundamental associations with both IDH mutational status and neuroglial developmental stage.
|
22415316 |
2012 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
IDH1 codon 132 and IDH2 codon 172 mutation status were determined by direct sequencing for a retrospective series of 100 patients with histologically diagnosed Astrocytomas WHO Grad II (A II), and investigated for association with patient outcome.
|
22528790 |
2012 |
Astrocytoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Strong associations were observed for astrocytomas with mutated IDH1 or IDH2 (grades 2-4) (OR=5.16-6.66, P=4.7×10(-12) to 2.2×10(-8)) but not for astrocytomas with wild-type IDH1 and IDH2 (smallest P=0.26).
|
22922872 |
2012 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
IDH1 and IDH2 are mutated in 50%-80% of astrocytomas, oligodendrogliomas, oligoastrocytomas, and secondary glioblastomas but are seldom mutated in primary glioblastomas.
|
23877318 |
2013 |
Astrocytoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Mutations in the isocitrate dehydrogenase (IDH) genes occur frequently in low-grade astrocytomas and oligodendrogliomas (World Health Organization [WHO] grade II), and in higher-grade gliomas (WHO grades III and IV) that arise after malignant progression of low-grade tumors.
|
23909061 |
2013 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In non 1p/19q codeleted LGGs, we demonstrated that (i) 11p loss is associated with astrocytoma phenotype and has an independent negative prognostic value, and (ii) 19q loss diminished the favorable prognostic value of IDH mutation.
|
24335697 |
2014 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Several investigations have searched a correlation between the BRAF gene fusions alterations and mutations at IDH1 and IDH2 genes in low grade pediatric astrocytomas.
|
24532263 |
2014 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
|
25427834 |
2015 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In patients with astrocytoma, the TERT promoter mutations only associated with poor survival (P < 0.0001); IDH mutations and 1p/19q deletions associated with increased survival (P = 0.0004).
|
25797251 |
2015 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that CDKN2A testing may provide further clinical aid in lower-grade glioma substratification beyond IDH mutation and 1p19q codeletion status, particularly in IDH/TP53 mutated astrocytomas.
|
25853694 |
2015 |
Astrocytoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We raise the question whether IDH-wild type high grade astrocytomas without microvascular proliferation or necrosis might best be classified as GBM, even if they lack the histologic hallmarks as required in the current WHO classification.
|
25943888 |
2015 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
This data poses a substantial challenge for the current practice of astrocytoma grading and risk stratification and is likely to have far-reaching consequences on the management of patients with IDH-mutant astrocytoma.
|
25962792 |
2015 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Those astrocytomas without IDH mutation tend to have a distinct genotype and a poor prognosis comparable to that of glioblastomas.
|
25975377 |
2015 |
Astrocytoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.
|
26087904 |
2015 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We analyzed markers, including IDH mutation(IDHmut), 1p19q codeletion(1p19qcodel), ATRX expression loss(ATRX loss) and p53 overexpression, and outcomes in 159 patients with WHO grade II oligodendroglioma, oligoastrocytoma, and astrocytoma (2003-2012).
|
26210286 |
2015 |
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Our data reveal that the methylation profiles in 23 of the 25 GC tumors corresponded to either IDH mutant astrocytoma (n = 6), IDH mutant and 1p/19q codeleted oligodendroglioma (n = 5), or IDH wild-type glioblastoma including various molecular subgroups, i.e., H3F3A-G34 mutant (n = 1), receptor tyrosine kinase 1 (RTK1, n = 4), receptor tyrosine kinase 2 (classic) (RTK2, n = 2) or mesenchymal (n = 5) glioblastoma groups.
|
26493382 |
2016 |